Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells.
about
A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells.Ibrutinib treatment improves T cell number and function in CLL patients.Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity.How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD
P2860
Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ibrutinib enhances IL-17 respo ...... arrow derived dendritic cells.
@ast
Ibrutinib enhances IL-17 respo ...... arrow derived dendritic cells.
@en
type
label
Ibrutinib enhances IL-17 respo ...... arrow derived dendritic cells.
@ast
Ibrutinib enhances IL-17 respo ...... arrow derived dendritic cells.
@en
prefLabel
Ibrutinib enhances IL-17 respo ...... arrow derived dendritic cells.
@ast
Ibrutinib enhances IL-17 respo ...... arrow derived dendritic cells.
@en
P2093
P2860
P1433
P1476
Ibrutinib enhances IL-17 respo ...... arrow derived dendritic cells.
@en
P2093
Abhay R Satoskar
Cesar Terrazas
Gayathri Natarajan
Jason A Dubovsky
Sanjay Varikuti
Steve Oghumu
P2860
P304
P356
10.1080/2162402X.2015.1057385
P50
P577
2015-06-09T00:00:00Z